12,116 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Cibc World Market Inc.

Cibc World Market Inc. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,116 shares of the biopharmaceutical company’s stock, valued at approximately $5,525,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. OFI Invest Asset Management grew its position in shares of Alnylam Pharmaceuticals by 5.8% during the third quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 22 shares in the last quarter. Howard Capital Management Inc. boosted its stake in Alnylam Pharmaceuticals by 2.9% during the 3rd quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock valued at $389,000 after acquiring an additional 24 shares during the last quarter. Frank Rimerman Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 2.0% during the 3rd quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock worth $570,000 after acquiring an additional 24 shares in the last quarter. Coastal Bridge Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 2.3% in the 3rd quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock worth $500,000 after purchasing an additional 25 shares during the last quarter. Finally, Meridian Financial Advisors LLC raised its stake in shares of Alnylam Pharmaceuticals by 3.5% in the 3rd quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock valued at $378,000 after purchasing an additional 28 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 1,510 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $362.87, for a total transaction of $547,933.70. Following the completion of the transaction, the executive vice president owned 22,511 shares in the company, valued at approximately $8,168,566.57. The trade was a 6.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jeffrey V. Poulton sold 2,780 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $1,008,778.60. Following the completion of the transaction, the executive vice president directly owned 57,465 shares of the company’s stock, valued at approximately $20,852,324.55. The trade was a 4.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 31,305 shares of company stock valued at $12,459,785 in the last ninety days. Insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ALNY. Jefferies Financial Group lowered their price objective on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a report on Thursday, October 30th. Stifel Nicolaus boosted their price target on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Chardan Capital reduced their price objective on Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a research note on Friday. Oppenheimer assumed coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price objective for the company. Finally, Royal Bank Of Canada dropped their target price on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a report on Tuesday, January 20th. Twenty-two investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $477.38.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Amvuttra is powering large revenue gains and Alnylam reported full-year product revenues near $3B with strong year‑over‑year growth; the company also reported profitability for the first time — a clear fundamental positive for long‑term earnings potential. Business Wire: Alnylam Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Catalyst from analyst support — some firms (e.g., TD Cowen) are maintaining Buy ratings and framing Amvuttra as the catalyst for a longer‑term profitability inflection. TipRanks: Amvuttra-Driven Profitability Inflection Supports Buy Rating
• Neutral Sentiment: FY‑2026 revenue guidance was updated to roughly $5.3–$5.8B (slightly wide band vs. consensus), leaving mixed readthroughs for near‑term estimates and valuation models. Business Wire: FY‑2026 Guidance
• Neutral Sentiment: Analysts have trimmed price targets (e.g., Chardan, Needham) but many kept Buy ratings — this tempers upside expectations while still signaling continued institutional conviction. Benzinga: Analyst Price Target Changes
• Negative Sentiment: Market reaction to the Q4 release was mixed: some outlets flagged EPS and revenue misses vs. specific consensus numbers while others reported an EPS beat — the inconsistent takeaways have created volatility and investor uncertainty. Zacks: Q4 Earnings Beat, Sales Miss MarketBeat: Q4 Snapshot
• Negative Sentiment: Management signaled higher long‑term R&D/spend to fund pipeline ambitions and flagged execution/scaling risks for global Amvuttra rollout — comments that prompted some investors to downgrade longer‑term profit expectations. Seeking Alpha: Investors Revise Future Profit Expectations TipRanks: Execution Risks Loom
• Neutral Sentiment: Reported short‑interest figures in the feeds are effectively zero/placeholder and not informative for current positioning — ignore as a market signal until clearer data is posted.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $314.40 on Friday. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. The firm has a market capitalization of $41.54 billion, a PE ratio of 183.86 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $495.55. The business’s fifty day moving average price is $374.98 and its two-hundred day moving average price is $424.68.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.61). The firm had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 119.85% and a net margin of 6.43%.The firm’s revenue was up 84.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.65) EPS. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.